您当前的位置:
Daratumumab (Synonyms:达雷木单抗; Anti-Human CD38, Human Antibody)
目录号 : KM17079 CAS No. : 945721-28-8 纯度 : 98%

Daratumumab (Anti-Human CD38) 是首创的特异性抗 CD38 单克隆抗体。Daratumumab 具有抗多发性骨髓瘤(MM) 的作用。Daratumumab 损伤了 MM 细胞的粘附,从而增加了 MM 对蛋白酶体抑制的敏感性。

规格 价格 是否有货 数量
1mg
In-stock
5mg
In-stock
10mg 询价 In-stock
50mg 询价 In-stock

Other Forms of Rapamycin:

KKL Med 的所有产品和服务仅用于科学研究,不能被用于人体,兽医,我们也不向个人提供产品和服务。
生物活性

Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody. Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition.

体外研究

Daratumumab (Anti-Human CD38) induces potent Ab-dependent cellular cytotoxicity in CD38-expressing lymphoma- and MM-derived cell lines.

体内研究

Daratumumab (i.p.; 0.5 mg/kg; 14 d after challenge with Daudi-luc cells) inhibits outgrowth of CD38-expressing tumor cells in mouse xenograft tumor models.

Animal Model: 8- to 10-wk-old C.B-17 SCID mice (luciferase-expressing Daudi cells)
Dosage: 0.5 mg/kg
Administration: I.p.; 14 day after challenge with Daudi-luc cells
Result: Effectively inhibited tumor growth compared with control-treated animals in which tumor grew rapidly and therefore required euthanasia on day 35. On day 28 and day 35, tumor size in Daratumumab-treated animals was significantly different from the control.
CAS号
945721-28-8
中文名称
达雷妥尤单抗; 达妥木单抗
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

临床试验
暂无相关参考文献
The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
动物实验计算换算器
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度 mg/ml;

DMSO母液配制方法 mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。

配置后的溶液总体积

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。